Skip to main content
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. — Investor Relations & Filings

Ticker · FULC ISIN · US3596161097 US Manufacturing
Filings indexed 465 across all filing types
Latest filing 2026-04-27 Interim / Quarterly Rep…
Country US United States of America
Listing US FULC

About Fulcrum Therapeutics, Inc.

https://www.fulcrumtx.com/

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule therapies for genetically defined diseases with high unmet medical needs. The company utilizes a proprietary technology platform to identify drug targets that can modulate gene expression, aiming to treat the root cause of a disease. This approach focuses on regulating genes that are incorrectly expressed. Fulcrum's pipeline is concentrated on creating disease-modifying treatments for rare conditions, with key programs in sickle cell disease and facioscapulohumeral muscular dystrophy (FSHD).

Recent filings

Filing Released Lang Actions
10-Q - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
Interim / Quarterly Report
2026-04-27 English
8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
Regulatory Filings
2026-04-27 English
SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
Major Shareholding Notification
2026-03-26 English
10-K - FULCRUM THERAPEUTICS, INC. (0001680581) (Filer)
Annual Report FY 2025
2026-02-24 English
8-K - FULCRUM THERAPEUTICS, INC. (0001680581) (Filer)
Regulatory Filings
2026-02-24 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.